Human GDF-15, His Tag (GD5-H5149) is expressed from E.coli cells. It contains AA Ala 197 - Ile 308 (Accession # Q99988-1).
Predicted N-terminus: Met
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 14.2 kDa. As a result of glycosylation, the protein migrates as 16-17 kDa under reducing (R) condition, and 27 kDa under non-reducing (NR) condition (SDS-PAGE).
Less than 1.0 EU per μg by the LAL method.
>90% as determined by reduced SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 60% ACN, 0.085% TFA. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human GDF-15, His Tag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Immobilized Human GDF-15, His Tag (Cat. No. GD5-H5149) at 1 μg/mL (100 μL/well) can bind Human GFR alpha-like Fc Chimera Protein with a linear range of 0.2-8 ng/mL (QC tested).
Growth Differentiation Factor 15 (GDF-15), also called Macrophage Inhibitory Cytokine 1 (MIC-1). Expression of MIC-1 mRNA in monocytoid cells is up-regulated by a variety of stimuli associated with activation, including interleukin 1β, tumor necrosis factor α (TNF-α), interleukin 2, and macrophage colony-stimulating factor but not interferon γ, or lipopolysaccharide (LPS). It is highly expressed in cardiomyocytes, adipocytes, macrophages, endothelial cells, and vascular smooth muscle cells in normal and pathological condition. GDF-15 increases during tissue injury and inflammatory states and is associated with cardiometabolic risk. Increased GDF-15 levels are associated with cardiovascular diseases such as hypertrophy, heart failure, atherosclerosis, endothelial dysfunction, obesity, insulin resistance, diabetes, and chronic kidney diseases in diabetes. Increased GDF-15 level is linked with the progression and prognosis of the disease condition.